Last reviewed · How we verify
Three-dose regimen of commercialized IPV
Three-dose regimen of commercialized IPV is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention. It is currently in Phase 2 development.
At a glance
| Generic name | Three-dose regimen of commercialized IPV |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (PHASE1)
- Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine. (PHASE2)
- Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Three-dose regimen of commercialized IPV CI brief — competitive landscape report
- Three-dose regimen of commercialized IPV updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about Three-dose regimen of commercialized IPV
What is Three-dose regimen of commercialized IPV?
Three-dose regimen of commercialized IPV is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention.
Who makes Three-dose regimen of commercialized IPV?
Three-dose regimen of commercialized IPV is developed by Jiangsu Province Centers for Disease Control and Prevention (see full Jiangsu Province Centers for Disease Control and Prevention pipeline at /company/jiangsu-province-centers-for-disease-control-and-prevention).
What development phase is Three-dose regimen of commercialized IPV in?
Three-dose regimen of commercialized IPV is in Phase 2.